Bio

Clinical Focus


  • Cancer > Gynecologic Cancer
  • Gynecologic Oncology

Academic Appointments


Professional Education


  • Fellowship:Memorial Sloan-Kettering Cancer Center (2008) NY
  • Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (2012)
  • Board Certification: Hospice and Palliative Medicine, American Board of Obstetrics and Gynecology (2010)
  • Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (2009)
  • Fellowship:David Geffen School of Medicine at UCLA (2007) CA
  • Residency:Johns Hopkins School of Medicine (2004) MD
  • Medical Education:American University of Beirut (2000) Lebanon

Publications

Journal Articles


  • HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review GYNECOLOGIC ONCOLOGY Karam, A., Berek, J. S., Stenson, A., Rao, J., Dorigo, O. 2008; 111 (3): 568-571

    Abstract

    The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target.We report the case of a 52-year-old patient with persistent Paget's disease of the vulva despite eight surgical excisions over a 15-year period. Immunohistochemistry demonstrated overexpression of the HER-2/neu protein in the vulva resection specimen. Treatment with Trastuzumab resulted in a significant regression of her disease and resolution of symptoms.Based on our case report, therapeutic targeting of HER-2/neu for patients with Paget's disease of the vulva using for example Trastuzumab is a potentially effective, alternative approach, and warrants further investigation.

    View details for DOI 10.1016/j.ygyno.2007.12.014

    View details for Web of Science ID 000261758000037

    View details for PubMedID 18252264

Stanford Medicine Resources: